Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Chemother ; 17(3): 289-96, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16038523

ABSTRACT

Our study focused on the influence of herpes simplex virus thymidine kinase (HSV-tk) expression and ganciclovir (GCV) treatment on the sensitivity of C6 glioma cells to frequently used chemotherapeutic drugs, i.e. adriamycin (ADR), cisplatin (CDDP), 5-fluorouracil (5-FU), and methotrexate (MTX). Transfection with HSV-tk revealed an increased sensitivity to GCV and CDDP and a decreased sensitivity to ADR and MTX. No significant differences were found in sensitivity to 5-FU. Combined treatment in a HSV-tk negative cell line revealed an additive effect when GCV was combined with ADR, whereas an antagonistic effect was found when GCV was combined with CDDP, 5-FU, or MTX. Comparable results were obtained in an HSV-tk positive cell line, apart from CDDP, which showed an additive effect. In conclusion, both HSV-tk transfection and subsequent GCV treatment can influence the sensitivity of tumor cells to various chemotherapeutic drugs in an antagonistic manner. Therefore, combining HSV-tk/GCV gene therapy with chemotherapy might not always be beneficial.


Subject(s)
Antineoplastic Agents/pharmacology , Brain Neoplasms/pathology , Ganciclovir/pharmacology , Glioma/pathology , Simplexvirus/enzymology , Simplexvirus/genetics , Thymidine Kinase/physiology , Animals , Antiviral Agents , Drug Interactions , Drug Screening Assays, Antitumor , Genetic Therapy , Rats , Transfection , Tumor Cells, Cultured
2.
Br J Cancer ; 91(12): 2079-85, 2004 Dec 13.
Article in English | MEDLINE | ID: mdl-15599382

ABSTRACT

Favourable pharmacokinetics of the prodrug are essential for successful HSVtk/ganciclovir (GCV) suicide gene therapy. [(18)F]FHPG PET might be a suitable technique to assess the pharmacokinetics of the prodrug GCV noninvasively, provided that [(18)F]FHPG mimics the behaviour of GCV. Since membrane transport is an important aspect of the pharmacokinetics of the prodrug, we investigated the cellular uptake mechanism of [(18)F]FHPG in an HSVtk expressing C6 rat glioma cell line and in tumour-bearing rats. The nucleoside transport inhibitors dipyridamol, NBMPR and 2-chloroadenosine did not significantly affect the [(18)F]FHPG uptake in vitro. Thymidine and uridine significantly decreased [(18)F]FHPG uptake by 84 and 58%, respectively, but an enzyme assay revealed that this decline was due to inhibition of the HSVtk enzyme rather than membrane transport. Nucleobase transport inhibitors, thymine and adenine, caused a 58 and 55% decline in tracer uptake, respectively. In vivo, the ratio of [(18)F]FHPG uptake in C6tk and C6 tumours decreased from 3.0+/-0.5 to 1.0+/-0.2 after infusion of adenine. Thus, in our tumour model, [(18)F]FHPG transport exclusively occurred via purine nucleobase transport. In this respect, FHPG does not resemble GCV, which is predominantly taken up via the nucleoside transporter, but rather acyclovir, which is also taken up via the purine nucleobase carrier.


Subject(s)
Biological Transport/physiology , Cell Membrane/metabolism , Fluorine Radioisotopes/pharmacokinetics , Genes, Transgenic, Suicide , Genetic Therapy , Animals , Antiviral Agents , Cell Line , Ganciclovir/pharmacokinetics , Glioma/diagnostic imaging , Herpesvirus 1, Human/genetics , Positron-Emission Tomography , Radioactive Tracers , Rats , Thymidine Kinase/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...